BIOLIGANDS ApS
CVR 26603110 · Private limited company (ApS) · Active · Low risk
BIOLIGANDS ApS is a Private limited company (ApS), founded on , based in Odense SV. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 20 annual reports have been published. The latest annual report (30 Jun 2025) shows equity of DKK 63k and a net result of DKK -7,129. CEO: Esben Nørgaard Flindt.
Bankruptcy risk for BIOLIGANDS ApS
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 26603110
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (24 years)
- Address
- c/o Esben N. Flindt, Skovalléen 4
5250 Odense SV - Municipality
- Odense
- Industry
- Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik - Share capital
- DKK 126k
- Employees
- 0 (2014)
- Auditor
- PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 23 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 90.7% |
| Current ratio | 1,076% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 2 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 0 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK -8,258 | DKK -5,904 |
| Net profit | DKK -7,129 | DKK -4,850 |
| Equity | DKK 63k | DKK 70k |
| Total assets | DKK 69k | DKK 72k |
| Cash | DKK 69k | – |
| Short-term debt | DKK 6,423 | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 183 | ||
| 1 Jul 2023 – 30 Jun 2024 | 171 | ||
| 1 Jul 2022 – 30 Jun 2023 | 171 | ||
| 1 Jul 2021 – 30 Jun 2022 | 141 | ||
| 1 Jul 2020 – 30 Jun 2021 | 155 | ||
| 1 Jul 2019 – 30 Jun 2020 | 148 | ||
| 1 Jul 2018 – 30 Jun 2019 | 152 | ||
| 1 Jul 2017 – 30 Jun 2018 | 154 | ||
| 1 Jul 2016 – 30 Jun 2017 | 151 | ||
| 1 Jul 2015 – 30 Jun 2016 | 151 | ||
| 1 Jul 2014 – 30 Jun 2015 | 174 | ||
| 1 Jul 2013 – 30 Jun 2014 | 168 | ||
| 1 Jul 2012 – 30 Jun 2013 | 167 | ||
| 1 Jul 2011 – 30 Jun 2012 | 160 | ||
| 1 Jul 2010 – 30 Jun 2011 | 166 | ||
| 1 Jul 2009 – 30 Jun 2010 | 151 | ||
| 1 Jul 2008 – 30 Jun 2009 | 166 | ||
| 1 Jul 2007 – 30 Jun 2008 | 153 | ||
| 1 Jul 2006 – 30 Jun 2007 | 142 | ||
| 1 Jul 2005 – 30 Jun 2006 | 153 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Esben Nørgaard Flindt | Current | |
| CEO | Karsten Kristiansen | ||
| Board | Rasmus Koefoed Petersen | Current | |
| Board | Karsten Kristiansen | ||
| Board | Hongbin Zhang | ||
| Board | Arne Fredens | ||
| Board | Lise Madsen | ||
| Board | Klaus Holmsberg | ||
| Board | Søren Stenderup | ||
| Owner (15%) | Karsten Kristiansen | Current | |
| Owner (15%) | Hongbin Zhang | Current | |
| Owner (15%) | Lise Madsen | Current | |
| Owner (15%) | Esben Nørgaard Flindt | Current | |
| Owner (15%) | Rasmus Koefoed Petersen | Current | |
| Owner (10%) | Bridge Bioresearch PLC | Current | |
| Auditor | Mogens Hansen | ||
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB | ||
| Founder | Karsten Kristiansen | Current | |
| Founder | Hongbin Zhang | Current | |
| Founder | SYDDANSK INNOVATION ApS | Current | |
| Founder | Lise Madsen | Current |
The CEOs' other companies
Esben Nørgaard Flindt – 1 other companies
- UBEAMION ApS Fusioneret
Address history (2 moves)
| c/o Esben N. Flindt, Skovalléen 4, 5250 Odense SV | |
| Forskerparken 10, 5230 Odense M | |
| c/o Syddansk Universitet, Campusvej 55, 5230 Odense M |
Former names
| BIOLIGANDS ApS | – now |
| BIOLIGANDS ApS UNDER STIFTELSE | – |
Employees per year
Similar companies in Odense
- Inverna Therapeutics ApS Odense M
- Uvigga Technologies ApS Odense C
- B Proteomics ApS Odense M
- Evosep Biolabs ApS Odense M
- Nordic microbes A/S Odense C
- Algiecel A/S Odense M
- QNTM Labs ApS Odense SØ
- Evosep ApS Odense M
- CELVIVO ApS Odense SØ
- Ovodan Biotech A/S Odense C
- MARTECH ApS Odense C
- HOUSETEST ApS Odense C
Questions and answers about BIOLIGANDS ApS
Has BIOLIGANDS ApS gone bankrupt?
No, BIOLIGANDS ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of BIOLIGANDS ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the CEO of BIOLIGANDS ApS?
Esben Nørgaard Flindt is the CEO of BIOLIGANDS ApS.
Who is the auditor of BIOLIGANDS ApS?
BIOLIGANDS ApS most recently used PricewaterhouseCoopersStatsautoriseret Revisionspartnerselskab.
When was BIOLIGANDS ApS founded?
BIOLIGANDS ApS was founded on 18 April 2002.
What is the equity of BIOLIGANDS ApS?
Equity was DKK 63k according to the annual report for the period ending 30 June 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.